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Abstract
Objective
Cross-sectional blindness prevalence surveys are essential to plan and monitor eye care
services. Incomplete or inaccurate reporting can prevent effective translation of research
findings. The Strengthening the Reporting of Observational Studies in Epidemiology
(STROBE) statement is a 32 item checklist developed to improve reporting of observational
studies. The aim of this study was to assess the completeness of reporting in blindness
prevalence surveys in low and middle income countries (LMICs) using STROBE.
Methods
MEDLINE, EMBASE and Web of Science databases were searched on April 8 2016 to iden-
tify cross-sectional blindness prevalence surveys undertaken in LMICs and published after
STROBE was published in December 2007. The STROBE tool was applied to all included
studies, and each STROBE item was categorized as ‘yes’ (met criteria), ‘no’ (did not meet
criteria) or ‘not applicable’. The ‘Completeness of reporting (COR) score’ for each manu-
script was calculated: COR score = yes / [yes + no]. In journals with included studies the
instructions to authors and reviewers were checked for reference to STROBE.
Results
The 89 included studies were undertaken in 32 countries and published in 37 journals. The
mean COR score was 60.9% (95% confidence interval [CI] 58.1–63.7%; range 30.8–
88.9%). The mean COR score did not differ between surveys published in journals with
author instructions referring to STROBE (10/37 journals; 61.1%, 95%CI 56.4–65.8%) or in
journals where STROBE was not mentioned (60.9%, 95%CI 57.4–64.3%; p = 0.93).
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Conclusion
While reporting in blindness prevalence surveys is strong in some areas, others need
improvement. We recommend that more journals adopt the STROBE checklist and ensure
it is used by authors and reviewers.
Introduction
Cross-sectional prevalence surveys are essential to plan and monitor local and national eye
care service delivery, as well as to monitor the prevalence and causes of blindness and visual
impairment globally. The latest estimate of global blindness drew on 227 prevalence surveys
from 84 countries undertaken between 1990 and 2012.[1] In the current global eye health
action plan the World Health Organization (WHO) called for more prevalence surveys to be
undertaken in low and middle income countries (LMICs) to enable evidence-informed plan-
ning.[2]
Resources for health research are scarce—especially in LMICs—so it is essential that
research findings are translated into health care policy and practice.[3] Incomplete or inaccu-
rate reporting of study methods and results hinders understanding of a study’s rigour, and
limits interpretation and effective translation of the findings. The manuscripts reporting blind-
ness and visual impairment prevalence surveys (hereafter referred to as blindness prevalence
surveys) do not always allow the reader to understand “what was planned, what was done,
what was found, and what conclusions were drawn”.[4] Incomplete reporting can also make
synthesis of evidence difficult or impossible.[5]
To improve reporting and facilitate critical appraisal of observational studies, including
cross-sectional surveys, the Strengthening the Reporting of Observational Studies in Epidemiol-
ogy (STROBE) statement was developed from a collaboration of epidemiologists, methodolo-
gists, statisticians, researchers and journal editors.[4] The STROBE statement was
disseminated in 2007 and provides a checklist of 32 items recommended for inclusion in the
reporting of observational studies. The items include aspects of study design, sample selection,
data collection, analysis, and potential bias.[4] To date it has been endorsed by more than 120
journals, including The Lancet and PLoS (see list at http://www.strobe-statement.org/).
This study aimed to assess the extent to which items in the STROBE cross-sectional check-
list (available for download at http://www.strobe-statement.org/) were reported in blindness
prevalence surveys published after STROBE was disseminated.
Methods
The search and study selection process is outlined in Box 1.
Data collection
Following discussion, we considered three of the 32 STROBE items not applicable to blindness
prevalence reporting a priori. Sensitivity analysis (item 12e) was considered not applicable
because we were focused on the reporting of the main result; choice of category boundaries for
continuous variables (item 16b) because blindness (the outcome) is categorical and dichoto-
mous (i.e. blind or not blind); and translating relative risk into absolute risk (item 16c) because
the outcome was a prevalence rate, not a measure of association. The remaining 29 items
were converted to questions to assist with consistent assessment. Three authors (JR, JP, VJ)
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independently reviewed one manuscript (not included in the sample) against the 29 STROBE
items to develop the questions and corresponding reviewer guidelines through discussion and
consensus. Five of the included manuscripts were then reviewed by the same three authors to
clarify any discrepancies in application of the questions and finalise the guidelines. Each
remaining manuscript in the sample was then reviewed by two authors (JR, JP, VJ, AP), with
one author (JR) reviewing all. Discrepancies were resolved by discussion and consensus. In
addition to the STROBE items, each included study was checked for a reference to STROBE,
and whether the Rapid Assessment of Avoidable Blindness (RAAB) methodology was used.
The 2015 SCImago Journal Rank (SJR) quartile was extracted for each ophthalmology journal
with an included study (http://www.scimagojr.com) and categorised as ophthalmology journal
top-quartile (Q1), ophthalmology journal outside top-quartile (Q2–4), or not ophthalmology
journal.
Data were collated using an Excel spreadsheet (Microsoft Corp, Redmond, Washington).
Each question was categorized as ‘yes’ (met criteria), ‘no’ (did not meet criteria) or ‘not
Box 1. Study search and selection process
Search
Date—April 8 2016
Databases—MEDLINE, EMBASE and Web of Science
Algorithm—‘blindness or vis impairment or low vision’ and ‘prevalence or rapid
assessment or population-based’.
Limits—Published between 1 January 2008 and 31 March 2016
Additional searching—Examined reference lists of published reviews of blindness
prevalence[6–9]
Process—Two researchers screened the titles of all citations identified during the ini-
tial search and the full-text manuscript was retrieved for review if the citation was poten-
tially relevant
Selection criteria
Inclusion
• conducted in countries classified by The World Bank as LMIC in 2014 (Gross National
Income <US$8,498) [10]
• presented cross-sectional population-based data
• provided information on blindness prevalence based on subjective visual acuity
measurement
• published in English
Exclusion
• undertaken in specific populations (e.g. in hospitals, ‘institutionalised’, ‘diabetics’)
• only included children
• only reported disease-specific blindness prevalence
• only reported blindness as an explanatory variable rather than as an outcome
STROBE and blindness prevalence surveys
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applicable’. We did not include a ‘partly’ option, to avoid it being used to negate having to
choose between yes and no.[11] Where a STROBE item contained several components, data
were collected for each component. For example, item 5 relates to reporting “. . ..setting, loca-
tion and relevant dates. . ...” so data were collected separately on i) setting/location and ii) rele-
vant dates. For item 5 to be assessed as adequate, both components needed to be reported.
To assess the extent to which STROBE was referred to by the journals in which included
studies were published, two authors (JR and AP) checked the publicly available instructions
for authors and reviewers. Each set of accessible instructions was categorised as STROBE
being: required, recommended, listed (without recommendation), or not mentioned.
Analysis
Analysis was completed using Excel and Stata 12.0 (StataCorp LP, TX). Descriptive analysis
included the number and proportion of manuscripts reporting i) each of the 29 STROBE
items, ii) use of RAAB methodology and iii) use of STROBE to guide reporting; the number
and proportion of manuscripts published in the top-quartile of ophthalmology journals; and
the number of journals including STROBE in instructions to i) authors and ii) reviewers.
The ‘Completeness of reporting (COR) score’ for each manuscript was calculated as the
‘yes’ answers as a proportion of the ‘yes + no’ answers: COR score (%) = [yes / (yes + no)]  100.
Consequently, the ‘not applicable’ items did not impact results.
Normality of COR scores was confirmed using distribution and probability plots. The
mean COR score and 95% confidence interval (CI) were calculated for each category of author
and reviewer instructions (i.e. required, recommended, listed, not mentioned, not accessible);
use of RAAB methodology (used RAAB or other methodology); and publication in the top-
quartile of ophthalmology journals (in the top-quartile, not in the top-quartile, not in an oph-
thalmology journal). One-way ANOVA or two-sample t-test was used to test for a difference
between the mean scores of the categories. The median and inter-quartile range of the COR
score within each manuscript section was calculated.
Sensitivity analysis. Some of the studies published in 2008 may have been prepared and
reviewed prior to the dissemination of STROBE in 2007, so we performed sensitivity analysis
to assess whether the inclusion of studies published in 2008 impacted our results. We calcu-
lated the COR score for studies published in 2008 and published after 2008, and used the two-
sampled t-test to assess the statistical significance of the difference between mean COR scores
in the two time periods.
Results
Summary of included studies
The search identified 2942 studies (Fig 1), of which 89 met the inclusion criteria (listed in S1
Table). The studies were undertaken in 32 countries and published in 37 different journals.
Eight of the 37 journals were in the top-quartile of ophthalmology journals (SJR quartile), and
published almost half of the included studies (n = 42). More than one-third of studies (37%,
n = 33) reported using the RAAB protocol. No manuscript reported using STROBE to guide
reporting.
Journals and STROBE
Of the 37 journals that published included studies, ten (27%) mentioned STROBE in instruc-
tions to authors—STROBE was listed without further instruction in four journals, recom-
mended in five journals, and required by one journal (PLOS ONE). Reviewer instructions
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were available for 15 (41%) journals; 12 of these did not mention STROBE, two listed STROBE
without further instruction and one (PLOS ONE) required adherence to reporting guidelines
(including STROBE) for publication (Table 1). Only one of the eight top-ranked ophthalmol-
ogy journals (that published three included studies) recommended the use of STROBE by
authors, and none with reviewer comments available referred to STROBE. In contrast, of the
15 ophthalmology journals outside the top-quartile, four journals (publishing seven studies)
listed STROBE and two journals (publishing four studies) recommended STROBE in instruc-
tions to authors; none mentioned STROBE in available reviewer instructions.
Completeness of reporting
COR scores ranged from 30.8% to 88.9%, with a mean of 60.9% (95%CI 58.1–63.7%; Table 1).
The mean COR score of studies that used RAAB methodology (58.8%, 95%CI 54.9–62.8%)
was not different to studies using other methodologies (62.2%, 95%CI 58.4–65.9%; t(87) =
1.15, p = 0.25). The mean COR score of studies published in the top-quartile of ophthalmology
Fig 1. Summary of study search and selection.
https://doi.org/10.1371/journal.pone.0176178.g001
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journals was higher than studies published in lower-ranked ophthalmology journals or non-
ophthalmology journals (Table 1; F(2,86) = 7.06, p = 0.001).
Inclusion of STROBE in instructions to authors did not tend to improve reporting—the
mean score of studies published in journals with instruction to authors that required, recom-
mended or listed STROBE (61.1%, 95%CI 56.4–65.8%) was not different to the score for stud-
ies published in journals not mentioning STROBE (60.9%, 95%CI 57.4–64.3%; t(87) = 0.09,
p = 0.93); the mean score of studies published in the journal requiring STROBE (68.2%, 95%
CI 64.0–72.4%) was higher than the score for the other studies combined (60.0%, 95%CI 57.0–
63.1%) but this was not statistically significant (t(87) = 1.87, p = 0.065). Inclusion of STROBE
in reviewer instructions also failed to improve reporting (64.3%, 95%CI 57.1–71.6% for
required/recommended/listed versus 64.6%, 95%CI 59.8–69.5% for not mentioned; t(36) =
0.07, p = 0.95).
Sensitivity analysis showed there was no difference in the mean COR score of those studies
published during 2008 and those published after 2008 (t(87) = 0.99, p = 0.32).
Reporting of STROBE items
Nine items were reported in 90% or more of the included manuscripts (Table 2): providing an
informative abstract (item 1b, 97%), scientific background (item 2, 96%) and study objectives
(item 3, 99%); presenting key elements of study design (item 4, 91%); describing eligibility cri-
teria (item 6, 92%); providing characteristics of study participants (item 14a, 90%) and number
of outcome events (item 15, 91%); and summarising (item 18, 90%) and interpreting (item 20,
94%) results.
Seven items were reported in less than one-third of manuscripts: defining outcomes and
diagnostic criteria (item 7, 31%); describing methods of measurement (item 8, 27%);
Table 1. Completeness of reporting (COR) score for journals publishing prevalence of blindness studies, by inclusion of STROBE in instructions
for authors and reviewers, and ophthalmology SCImago Journal Rank.
Number of journals Number of manuscripts Mean COR score* (95%CI), %
Author instructions
STROBE required 1 10 68.2 (64.0–72.4)
STROBE recommended 5 8 53.1 (43.6–62.6)
STROBE listed 4 7 60.2 (52.3–68.0)
STROBE not mentioned 27 64 60.9 (57.4–64.3)
Reviewer instructions
STROBE required 1 10 68.2 (64.0–72.4)
STROBE recommended - - -
STROBE listed 2 2 45.0 (16.7–73.3)
STROBE not mentioned 12 26 64.6 (59.8–69.5)
Instructions not accessible 22 51 58.2 (54.5–62.0)
SCImago Journal Rank 2015**
Ophthalmology top-quartile, Q1 8 42 66.1 (62.4–69.9)
Ophthalmology Q2–4 15 22 55.3 (51.0–59.7)
Not ophthalmology 14 25 57.2 (51.5–62.8)
Total 37 89 60.9 (58.1–63.7)
CI: confidence interval
*Completeness of reporting (COR) score is the proportion of the 29 included items adequately reported (items 12e, 16b and 16c removed a priori as they
were considered not applicable to reporting blindness prevalence surveys).
** available at http://www.scimagojr.com
https://doi.org/10.1371/journal.pone.0176178.t001
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Table 2. Reporting of STROBE items in 89 blindness prevalence surveys published between January 2008 and March 31 2016.
STROBE
Item
STROBE Description Question answered Individual component
adequate
Overall item
adequate* n (%)
NA No Yes
Abstract
1a Indicate the study’s design with a commonly used term in
the title or the abstract
Is the design referred to as either ‘cross-sectional’ or
‘population-based survey’ in the title or abstract?
- 40 (45) 49 (55) 49 (55)
1b Provide in the abstract an informative and balanced
summary of what was done and what was found
Does the abstract provide an informative summary of
what was done and found?
1 (1) 3 (3) 85 (96) 85 (97)
Introduction
2 Explain the scientific background and rationale for the
investigation being reported
Is the scientific background and rationale for the
investigation reported?
- 4 (4) 85 (96) 85 (96)
3 State specific objectives, including any pre-specified
hypotheses
Are objectives and /or hypotheses reported? - 1 (1) 88 (99) 88 (99)
Methods
4 Present key elements of study design early in the paper Are the key elements of the study design presented
before the end of methods?
- 8 (9) 81 (91) 81 (91)
5 Describe the setting, locations, and relevant dates,
including periods of recruitment, exposure, follow-up, and
data collection
Are the setting/locations reported? - 6 (7) 83 (93) 71 (80)
Are the dates of the survey reported? - 13 (15) 76 (85)
6 Give the eligibility criteria, and the sources and methods
of selection of participants
Are eligibility criteria, and sources and methods of
selection of participants provided?
- 7 (8) 82 (92) 82 (92)
7 Clearly define all outcomes, exposures, predictors,
potential confounders, and effect modifiers. Give
diagnostic criteria, if applicable
Is the outcome (i.e. blindness) defined in the
introduction or methods, or the 1st time it is
mentioned in results (e.g. <3/60 in the better eye)?
- 7 (8) 82 (92) 28 (31)
Are diagnostic criteria for blindness described (i.e.
how many letters on the line were correct/incorrect to
be allocated to that level of vision)?
- 60 (67) 29 (33)
8 For each variable of interest, give sources of data and
details of methods of assessment (measurement).
Describe comparability of assessment methods if there is
more than one group
Is vision assessment described (in sufficient detail to
be replicated)?
- 49 (55) 40 (45) 24 (27)
If blindness is reported by age groups, is the method
by which age was ascertained described?
32 (36) 38 (43) 19 (21)
If blindness is reported by another social variable
(e.g. education), is the method by which this was
ascertained described?
54 (61) 20 (22) 15 (17)
9 Describe any efforts to address potential sources of bias Was there any effort to address potential sources of: - 23 (26) 66 (74) 33 (37)
–selection bias when selecting clusters?
–selection bias when selecting individuals within
clusters?
- 31 (35) 58 (65)
–measurement bias? (e.g. inter-rater agreement) - 45 (51) 44 (49)
10 Explain how the study size was arrived at Was the method of establishing the study size
explained AND the calculated size provided?
- 29 (33) 60 (67) 60 (67)
11 Explain how quantitative variables were handled in the
analyses. If applicable, describe which groupings were
chosen and why
Did they explain how quantitative variables were
handled in the analysis?
- 46 (52) 43 (48) 43 (48)
12a Describe all statistical methods, including those used to
control for confounding
Were statistical methods for calculating blindness
prevalence described?
- 48 (54) 41 (46) 41 (46)
12b Describe any methods used to examine subgroups and
interactions
If analysis is undertaken to compare blindness in
subgroups, is the analysis explained in methods?
48 (54) 13 (15) 28 (31) 28 (68)
12c Explain how missing data were addressed (In the methods) is it reported how missing data were
addressed?
- 86 (97) 3 (3) 3 (3)
12d If applicable, describe analytical methods taking account
of sampling strategy
If age standardization is reported in results, is the
process explained in methods?
49 (55) 26 (29) 14 (16) 14 (34)
Results
13a Report numbers of individuals at each stage of study Are the number of people enumerated and the
number examined provided?
- 12 (13) 77 (87) 77 (87)
13b Give reasons for non-participation at each stage Are the reasons for non-participation provided? - 50 (56) 39 (44) 39 (44)
13c Consider use of a flow diagram† Was a flow diagram used? 87 (98) - 2 (2) -
14a Give characteristics of study participants (eg
demographic, clinical, social)
Were participants described by (at least) age and
sex?
- 9 (10) 80 (90) 80 (90)
(Continued)
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explaining how missing data were managed (item 12c, 3%); reporting missing data (item 14b,
33%); discussing study limitations (item 19, 17%) and generalisability (item 21, 30%); and pro-
viding the name and role of the funder (item 22, 22%). Partial reporting within a number of
these items reduced the overall score. For example, for item 7 blindness was commonly
defined (in 92% of manuscripts) while diagnostic criteria were not (33%); and for item 22 the
funder was often named (78%) but their role was not defined (17%; Table 2).
Overall, the extent of reporting varied notably across and within manuscript sections, with
applicable items being most commonly reported in the Introduction (median COR
Score = 97%; 2 items: 99% and 96%), followed by the Abstract (76%; 2 items: 97% and 55%),
Results (65%, IQR 41–87), Methods (47%, IQR 33–71) and Discussion (51%, IQR 22–90).
Discussion
The WHO’s global eye health action plan has called for more blindness prevalence surveys to
be undertaken in LMICs.[2] Our results indicate that reporting of such surveys must be
improved to maximise effective translation of the findings, and to aid synthesis. No single
blindness prevalence manuscript published since the dissemination of STROBE adhered to
more than 90% of STROBE items, and no single STROBE item was adequately addressed
Table 2. (Continued)
STROBE
Item
STROBE Description Question answered Individual component
adequate
Overall item
adequate* n (%)
NA No Yes
14b Indicate number of participants with missing data for each
variable of interest
Are the number of participants with missing vision
data reported (or can we tell from the data
presented)?
- 60 (67) 29 (33) 29 (33)
15 Report numbers of outcome events or summary
measures
Are the number of blind participants reported? - 8 (9) 81 (91) 81 (91)
16a Give unadjusted estimates and, if applicable, confounder-
adjusted estimates and their precision (eg, 95%
confidence interval).
Did they report [unadjusted and/or adjusted
prevalence estimate] AND 95%CI?
1 (1)‡ 14 (16) 74 (83) 74 (84)
17 Report other analyses done—eg analyses of subgroups
and interactions, and sensitivity analyses
Was any analysis undertaken to compare blindness
in subgroups?
1 (1)‡ 48 (54) 40 (45) 40 (45)
Discussion
18 Summarise key results with reference to study objectives Are key results summarised with reference to the
study objectives?
- 9 (10) 80 (90) 80 (90)
19 Discuss limitations of the study, taking into account
sources of potential bias or imprecision. Discuss both
direction and magnitude of any potential bias
Did they discuss the limitations of the study, taking
into account sources of potential bias/ imprecision
(both direction and magnitude) in relation to:
–sample selection/representativeness;
- 70 (79) 19 (21) 15 (17)
–other sources of potential bias or imprecision - 48 (54) 41 (46)
20 Give a cautious overall interpretation of results
considering objectives, limitations, multiplicity of analyses,
results from similar studies, and other relevant evidence
Did they provide an overall interpretation of results
considering objectives, analyses, results from similar
studies and other relevant evidence?
- 5 (6) 84 (94) 84 (94)
21 Discuss the generalisability (external validity) of the study
results
Did they discuss the generalisability (external
validity) of the study results?
- 62 (70) 27 (30) 27 (30)
22 Give the source of funding and the role of the funders for
the present study
Is the funding source provided? - 20 (22) 69 (78) 20 (22) §
Is the role of the funder provided? 6 (7) 69 (78) 14 (17)
Items 12e, 16b, 16c removed a priori as they were considered not applicable to reporting blindness prevalence surveys.
*to be assessed as a yes, individual components must be assessed as yes; NA not included; proportion (%) = yes/(yes+no).
† as enumeration and participation were the only stages involved, we categorized this as yes or NA.
‡ one study found no blind participants (only vision impaired) so could not report this.
§ The role of funders was NA for 6 studies that received no specific funding; these studies were included in the numerator for the overall assessment of this
item.
https://doi.org/10.1371/journal.pone.0176178.t002
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across all manuscripts (Table 2). Reporting was weakest in the Methods and Discussion sec-
tions. If authors improved adherence to STROBE, readers would better understand what was
done and therefore whether the survey findings (i.e. blindness prevalence estimates) are valid.
[12] Further, better adherence to STROBE would enable evidence-informed planning and
monitoring of eye care services, and more accurate global estimates when results are
synthesised.
Journal endorsement and use of reporting guidelines are expected to improve completeness
of reporting. However, with the exception of CONSORT (CONsolidated Standards of Report-
ing Trials), few evaluations have assessed whether journal endorsement of guidelines improves
reporting.[13] The CONSORT guidelines were launched in 1997 to improve reporting of ran-
domised control trials (RCTs). A systematic review found that journals endorsing CONSORT
improved reporting of RCTs, but the review also identified a gap between journals endorsing
CONSORT and consistently implementing it.[14] Our results reflect a similar gap for
STROBE—endorsement of STROBE in a journal’s instructions for authors and reviewers was
not reflected by better reporting of the blindness prevalence surveys they published (Table 1).
This lack of translation suggests that endorsement of reporting guidelines without enforce-
ment by journal editors and reviewers is ineffectual. Some journals are trying to strengthen
author application of STROBE. For example, The BMJ and PLOS Medicine require authors to
complete the STROBE checklist to identify accomplishment of each item, with the checklist
published alongside the study.[15, 16] This strategy could be implemented by ophthalmology
journals, and further strengthened by requiring reviewers to assess adherence to STROBE
when undertaking reviews.[17] We identified weaker reporting in lower-ranked ophthalmol-
ogy journals (2015 SJR quartiles 2−4), suggesting these journals may benefit most from the use
of STROBE to assist authors and reviewers.
STROBE development intentionally avoided being prescriptive,[4] which resulted in gener-
alized guidelines,[12] some of which are not applicable to blindness prevalence surveys. We
omitted three items from our assessment a priori, and others (such as the use of a flow diagram
[13c]) seem less applicable after undertaking the review. The COR score calculation gave equal
weight to each item in the STROBE checklist. As some items are arguably less important for
reporting blindness prevalence surveys, the COR score is an imperfect summary measure.
With the anticipated increase in surveys in the coming years, development of specific reporting
guidelines for blindness prevalence surveys may be beneficial, and could include the identifica-
tion of ‘essential’ items, as well as items that are not applicable. Fortunately, the process fol-
lowed to develop such guidelines in other fields are available from the Equator Network
(http://www.equator-network.org/). Until specific guidelines become available, the existing
STROBE checklist can be used by authors of all blindness prevalence surveys.
Excluding some STROBE items from our assessment limits the comparability of our find-
ings with other studies. Also, few studies report analysis for cross-sectional surveys separately
to cohort and case-control studies. Despite these differences, our mean COR score (60.9%,
95%CI 58.1–63.7%) was similar to equivalent rates of ‘yes’/ ‘applicable’ items reported from
STROBE assessment in diverse fields including orthopaedics (58%),[18] hand surgery (58%
post-STROBE dissemination),[19] and dermatology (58% post-STROBE).[20]
RAAB surveys are the most commonly published blindness prevalence survey methodol-
ogy. Reasons for this include that RAABs are shorter and less expensive than traditional sur-
veys; the protocol and analysis software are readily available;[21] and RAABs have been
designed to be implemented by local eye health workers following standardised training.[22]
We found that the completeness of reporting of RAAB and non-RAAB surveys was similar.
With the number of RAABs set to increase in the coming years, expanding the focus on report-
ing and the use of guidelines during RAAB training is a promising strategy to improve
STROBE and blindness prevalence surveys
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reporting of blindness prevalence surveys. In addition, ongoing monitoring of reporting qual-
ity may be beneficial, using the COR score (or similar), as well as graphical displays.
This analysis must be interpreted in the context of its limitations. Assessment of included
studies was unblinded, which may have introduced bias through presumed reputation of
some authors.[23] This potential for bias was lessened by two of the four reviewers being out-
side the field of eye care. Reviewer fatigue may also have been an issue, as data collection
took place over a five-month period―we attempted to reduce this by developing assessment
guidelines, using two reviewers for each study, and requiring any discrepancy to be discussed
and resolved. In addition to English language studies, the search found 12 non-duplicate
studies in Chinese and four in Spanish that we were unable to assess. The STROBE statement
is available in these languages,[24] and could be applied by researchers fluent in reading
them. Finally, we were unable to assess whether STROBE was included in instructions to
authors at the time of submission of each individual manuscript. We believe this had little
influence on our results―less than one-third of journals referred to STROBE in 2016, and it
is unlikely that journals previously included STROBE in their instructions and subsequently
removed it.
While not a limitation, to assist interpretation of our results it must be noted that we
assessed completeness of reporting and not methodological quality or risk of bias of the
included studies.[5] That is, we recorded whether an item was reported in sufficient detail to
enable appraisal (e.g. steps taken to reduce bias in cluster selection), not whether the methods
employed were sufficient to achieve the specific aim (e.g. avoid selection bias). Further, it is
possible some of the checklist items were fulfilled during study design, implementation or
analysis, but without complete reporting this remains unknown.
A scan of the literature suggests this is the first analysis of completeness of reporting of
blindness prevalence surveys. It has revealed strong reporting in some areas, with other areas
in need of improvement. The anticipated increase in surveys in LMICs in the coming years[2]
provides the impetus for stakeholders to identify strategies to improve the quality of reporting
and therefore increase the utility of survey findings. Supporters of research (international and
national non-government organisations as well as academic institutions) could extend support
beyond study implementation to also strengthen local research capabilities, including report-
ing. Endorsement of STROBE by journals should help, but only if its use is consistently
enforced by editorial staff and reviewers. We recommend that ophthalmology journals adopt
the STROBE checklist and ensure it is used by authors and reviewers.
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